Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trodusquemine is a naturally occurring aminosterol and cholestane originally isolated from the liver of the dogfish shark (*Squalus acanthias*), but now also synthesized in laboratories. It acts as a non-competitive allosteric inhibitor of protein tyrosine phosphatase 1B (PTP1B), which plays a key role in insulin and leptin signaling pathways. By inhibiting PTP1B centrally and peripherally, trodusquemine enhances insulin sensitivity and glycemic control. It also suppresses feeding behavior by acting on the hypothalamus’s paraventricular nucleus and modulates neuropeptide expression associated with weight loss. In addition to its metabolic effects, trodusquemine has demonstrated regenerative properties in animal models (e.g., heart regeneration), anti-atherosclerotic activity by preventing macrophage foam cell formation, broad-spectrum antimicrobial activity, neuroprotective effects (including reduction of toxic protein aggregates relevant to neurodegenerative diseases), antitumor activity through inhibition of tumor cell proliferation via PTP1B inhibition or other mechanisms such as dopamine/norepinephrine reuptake inhibition[2][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trodusquemine.